BUSINESS
Eris Lifesciences net profit jumps 39 percent YoY to Rs 134 crore
Revenue rose 6.9 percent YoY to Rs.792 crore.
BUSINESS
Biocon reports Rs 85 crore net profit in Q2FY26
Consolidated revenue grew 11% year-on-year to Rs. 4,389 crore, led by a 25% jump in biosimilars, which contributed 61% of segmental revenue.
BUSINESS
Weight loss drug Wegovy to become cheaper as Novo Nordisk cuts prices by up to 37%
The company announced that the starting dose of Wegovy (0.25 mg) will now cost Rs 2,712 per week, down from Rs.4,336
BUSINESS
Apollo Hospitals says on track for Rs 25,000-crore revenue ahead of FY27 IPO for omnichannel pharmacy & distribution arm
Backed by private equity firm Advent International, Apollo HealthCo—which combines offline pharmacy distribution, digital health services via Apollo 24/7, and the soon-to-be-merged Keimed—has seen a sharp turnaround in profitability.
BUSINESS
Cough and cold medicine sales dip in October as syrup safety concerns mount
This marks the first time in three years that October volumes failed to surpass September, despite the onset of seasonal respiratory illnesses.
BUSINESS
Novo Nordisk partners with Emcure to distribute weight loss drug semaglutide in India
The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access beyond metro cities and premium clinics.
BUSINESS
DCGI signals end of grace period for small drugmakers, orders immediate inspections under revised Schedule M
The directive from the DCGI, signals an end to the current extension of timeline until December 31, 2025 for thousands of small and medium-sized pharmaceutical firms to comply with the Revised Schedule M rules, warning that "strict action" will be initiated against units that fail to meet the new quality mandates.
BUSINESS
Cipla's Next Chapter: Achin Gupta to succeed Umang Vohra as global CEO, faces innovation challenge
Gupta, currently the Global Chief Operating Officer, will serve as MD & Global CEO-designate starting January 1, 2026. Company executives describe him as Mr Cool and no stranger to innovation and licensing deals.
BUSINESS
Lilly’s Mounjaro is India’s top-selling drug in October
The sales rose to nearly Rs 100 crore, a month-on-month growth of around 25%
BUSINESS
Apollo Hospitals net profit zooms 26% to Rs 477 crore in Q2FY26
Revenue rose 13% YoY to Rs 6,304 crore, while EBITDA grew 15% to Rs 941 crore, with overall margins holding steady at 14.9%.
BUSINESS
GSK India posts Rs 255 crore net profit in Q2FY26
Revenue from operations stood at ₹974 crore, reflecting a temporary topline dip due to GST-related transitions, seasonal disruptions, and a fire at a contract manufacturing site that impacted supply of select general medicines brands.
BUSINESS
Sun Pharma backs speciality play, lines up launches in US amid uncertainty over tariffs
Despite macro uncertainties, Sun Pharma has been bullish on its specialty pipeline and global expansion.
BUSINESS
Syngene net profit drops 37% to Rs 67 crore in Q2FY26
“Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing,” said Peter Bains, Managing Director and CEO.
BUSINESS
Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business
The company attributed the loss to decline to inventory destocking by a key customer in a large on-patent CDMO order and slower order inflows amid inconsistent recovery in US biopharma funding.
BUSINESS
Sun Pharma net profit rises 2.6%YoY to Rs 3,118 crore in Q2FY26
Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.
BUSINESS
Gland Pharma net profit rises 12%YoY to Rs 183.7 crore in Q2FY26
Consolidated revenue rose 6% to ₹1487 crore, while EBITDA grew 6% to ₹313.9 crore.
BUSINESS
Dr.Ajaikumar-backed Inviga Healthcare Fund picks up 21% stake in Forus Health
Forus Health, best known for its 3nethra series of eye screening devices, has screened over 22 million patients across 75 countries.
BUSINESS
Wockhardt swings to profit in Q2, novel antibiotic Zaynich gets breakthrough status in Saudi Arabia
Revenue for the quarter stood at ₹782 crore, up from ₹738 crore in Q1. EBITDA margins improved to 20.5%, up from 13.7% in the previous quarter.
BUSINESS
Narayana Health targets 22% RoCE by FY30 in UK bet, eyes private pay growth to boost margins
The Indian hospital chain, known for its low-cost, high-throughput model, is entering the UK market through its Cayman Islands subsidiary, acquiring the secondary care division of Practice Plus Group — the fifth-largest private healthcare network in the UK and fourth-largest NHS service provider.
BUSINESS
Medikabazaar co-founder alleges Rs 264 crore fraud in FIR against board and investors
In a complaint registered by Mumbai’s Economic Offences Wing (EOW) on October 30, Tiwari accused directors from Creaegis, Healthquad, and Ackerman Van Haaren of diverting company funds to non-existent entities
BUSINESS
Lupin stands tall in digital therapeutics as others struggle
Unlike competitors that rushed to market, Lupin spent its early years conducting trials and publishing peer-reviewed studies — a strategy that CEO Sidharth Srinivasan says has been key to survival.
BUSINESS
Narayana Health buys UK’s Practice Plus for Rs 1,930 crore to expand global footprint
The acquisition gives Narayana Hrudayalaya a strategic entry into the mature UK healthcare market, which is witnessing a shift toward day-care procedures and increased private-pay penetration.
BUSINESS
Fertility startup Pluro raises Rs 125 crore in Series A round led by Bessemer, valuing the firm at Rs 1,000 crore
The latest funding round valued the startup at Rs 1,000 crore and saw participation from prominent angel investors including Vikram Chatwal (MediAssist), Dharmil Sheth and Hardik Dedhia (PharmEasy), and Salil Musale (Astarc Ventures).
BUSINESS
Umang Vohra, Cipla’s outgoing CEO says task achieved, ‘not retiring’ from sector
Vohra was the second executive roped in from outside Cipla’s promoter family to lead the drug maker. Under his watch, Cipla saw a sharp improvement in profitability, driven by strategic expansion in chronic therapies, operational efficiencies and global partnerships.
